Bismuth Subcitrate

Summary

Bismuth Subcitrate (CHEMBL1744033) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including helicobacter pylori infectious disease and lymphoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1744033
Name	Bismuth Subcitrate
Type	Small molecule
Max phase	3

Also known as: Bismuth subcitrate, Colloidal bismuth subcitrate, Tripotassium dicitratobismuthate, bismuth subcitrate, BISMUTH SUBCITRATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Helicobacter pylori infectious disease	3	MONDO:0006781	EFO:1000961
lymphoma	2	MONDO:0005062	EFO:0000574

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE4	5
PHASE2	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01335334	PHASE4	UNKNOWN	H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study
NCT02894268	PHASE4	UNKNOWN	Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy
NCT04101708	PHASE4	UNKNOWN	A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients
NCT04853875	PHASE4	COMPLETED	ILTHPI - Comparison of Medicament Containing Tetracycline, Metronidazole, Bismuth Versus Amoxicillin, Metronidazole, Clarithromycin
NCT06143124	PHASE4	UNKNOWN	Bismuth Quadruple Therapy Versus Standard Triple Therapy
NCT04107194	PHASE3	UNKNOWN	Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.
NCT00003151	PHASE2	COMPLETED	Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma
NCT01876108	PHASE2	COMPLETED	The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease
NCT06216639	Not specified	UNKNOWN	Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).